Zacks Investment Research upgraded shares of Synthorx (NASDAQ:THOR) from a hold rating to a buy rating in a research report report published on Saturday, Zacks.com reports. Zacks Investment Research currently has $22.00 price target on the medical instruments supplier’s stock.
According to Zacks, “Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company’s product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. “
Several other research firms have also weighed in on THOR. HC Wainwright set a $30.00 price objective on Synthorx and gave the stock a buy rating in a research report on Wednesday, September 18th. ValuEngine lowered Synthorx from a buy rating to a hold rating in a research report on Wednesday, September 25th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Synthorx has an average rating of Buy and an average target price of $24.33.
Synthorx (NASDAQ:THOR) last posted its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.12. On average, research analysts predict that Synthorx will post -1.81 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of THOR. Morgan Stanley increased its position in Synthorx by 9,312.2% in the 2nd quarter. Morgan Stanley now owns 123,112 shares of the medical instruments supplier’s stock valued at $1,663,000 after buying an additional 121,804 shares in the last quarter. BlackRock Inc. increased its position in Synthorx by 25.7% in the 2nd quarter. BlackRock Inc. now owns 543,305 shares of the medical instruments supplier’s stock valued at $7,341,000 after buying an additional 111,165 shares in the last quarter. Citadel Advisors LLC bought a new stake in Synthorx in the 2nd quarter valued at about $787,000. Russell Investments Group Ltd. bought a new stake in Synthorx in the 3rd quarter valued at about $800,000. Finally, Vanguard Group Inc. increased its position in Synthorx by 8.4% in the 2nd quarter. Vanguard Group Inc. now owns 336,963 shares of the medical instruments supplier’s stock valued at $4,552,000 after buying an additional 26,085 shares in the last quarter. 65.66% of the stock is owned by institutional investors and hedge funds.
Synthorx Company Profile
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.